1 March 2014 in Neuroscience & Biobehavioral Reviews
15 January 2013 in Molecular Psychiatry
3 April 2023 in IEEE Transactions on Affective Computing
Recently, wearable emotion recognition based on peripheral physiological signals has drawn massive attention due to its less invasive nature and its applicability in real-life scenarios. However, how to effectively fuse multimodal data remains a challenging problem. Moreover, traditional fully-supervised based approaches suffer from overfitting given limited labeled data. To address the above issues, we propose a novel self-supervised learning (SSL) framework for wearable emotion recognition, where efficient multimodal fusion is realized with temporal convolution-based modality-specific encoders and a transformer-based shared encoder, capturing both intra-modal and inter-modal correlations. Extensive unlabeled data is automatically assigned labels by five signal transforms, and the proposed SSL model is pre-trained with signal transformation recognition as a pretext task, allowing the extraction of generalized multimodal representations for emotion-related downstream tasks. For evaluation, the proposed SSL model was first pre-trained on a large-scale self-collected physiological dataset and the resulting encoder was subsequently frozen or fine-tuned on three public supervised emotion recognition datasets. Ultimately, our SSL-based method achieved state-of-the-art results in various emotion classification tasks. Meanwhile, the proposed model was proved to be more accurate and robust compared to fully-supervised methods on low data regimes.
18 November 2014 in Schizophrenia Research and Treatment
Objective.Despite evidence from case series, the comorbidity of eating disorders (EDs) with schizophrenia is poorly understood. This review aimed to assess the epidemiological and clinical characteristics of EDs in schizophrenia patients and to examine whether the management of EDs can be improved.Methods.A qualitative review of the published literature was performed using the following terms: “schizophrenia” in association with “eating disorders,” “anorexia nervosa,” “bulimia nervosa,” “binge eating disorder,” or “night eating syndrome.”Results.According to our literature review, there is a high prevalence of comorbidity between schizophrenia and EDs. EDs may occur together with or independent of psychotic symptoms in these patients. Binge eating disorders and night eating syndromes are frequently found in patients with schizophrenia, with a prevalence of approximately 10%. Anorexia nervosa seems to affect between 1 and 4% of schizophrenia patients. Psychopathological and neurobiological mechanisms, including effects of antipsychotic drugs, should be more extensively explored.Conclusions.The comorbidity of EDs in schizophrenia remains relatively unexplored. The clearest message of this review is the importance of screening for and assessment of comorbid EDs in schizophrenia patients. The management of EDs in schizophrenia requires a multidisciplinary approach to attain maximized health outcomes. For clinical practice, we propose some recommendations regarding patient-centered care.
27 April 2020 in European Psychiatry
Background.: The aim of the present study was to estimate prevalence rates of psychiatric and substance use disorders in male and female prisoners on admission to prison in the north of France and compare the frequency of these disorders to the general population. Methods.: This cross-sectional survey on Mental Health in the Prison Population (MHPP), conducted between March 2014 and April 2017, interviewed 653 randomly selected men and women who had recently been committed to the French general population prison system in the Nord and Pas-de-Calais departments. For each subject, the Mini International Neuropsychiatric Interview (MINI), a standardized psychiatric interview, was used to screen for psychiatric and substance use disorders. The prevalence rates were then compared with data from the Mental Health in the General Population (MHGP) survey, a general population survey that used the same assessment methodology as MHPP in the Nord and Pas-de-Calais departments. A control sample was taken from the MHGP survey with a ratio of one case (MHPP) to three controls (MHGP) matching on age and sex. Results.: The sample was primarily composed of French men, most of them single with low educational levels at the time of imprisonment. The mean age was 31.7 (standard deviation = 9.9; min = 18; max = 67). Most of the subjects included were first-time prisoners. The prevalence of affective disorders among newly incarcerated individuals was 31.2% with higher rates for major depressive disorder (27.2%). The prevalence of anxiety disorders was 44.4% with higher rates for generalized anxiety disorder (25.2%). The prevalence of psychotic syndromes was 6.9%. The prevalence of substance use disorders was 53.5% and a suicide risk was identified in 31.4% of the prisoners interviewed. Higher prevalence rates were found in the MHPP when compared with the MHGP for all psychiatric and substance use disorders assessed except for dysthymia and current isolated psychotic syndrome. Conclusions.: Our study shows very high levels of prevalence for psychiatric and substance use disorders in recently committed French prisoners.
1 June 2013 in Schizophrenia Research